首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

1629597

HIV 臨床試驗市場：按階段、依研究設計、按申辦者類型、按適應症、按地區

HIV Clinical Trials Market, By Phase, By Study Design, By Sponsor Type, By Indication, By Geography, By Geography

出版日期: 2024年12月17日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球愛滋病毒臨床試驗市場規模為14.8億美元，預計2031年將達21.9億美元，2024年至2031年複合年成長率為5.8%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	14.8億美元
實際資料	2019-2023	預測期	2024-2031
預測 2024-2031 年複合年成長率：	5.80%	2031年價值預測	21.9億美元

圖：HIV 臨床試驗市場的區域佔有率（%）（2024 年）

全球愛滋病毒臨床試驗市場的成長是由世界各地正在進行的越來越多的臨床試驗推動的，這些臨床試驗旨在開發用於愛滋病毒治療和預防的有效治療方法和疫苗。由於HIV患者數量不斷增加，生物製藥公司和研究機構正在加大對HIV臨床研發活動的投入。此外，人們對臨床試驗以及私營和政府部門的可用性的認知不斷提高正在推動市場擴張。然而，愛滋病毒臨床試驗的持續時間長、高成本可能是一個挑戰。

市場動態

全球愛滋病毒臨床試驗市場的成長主要是由於全球愛滋病毒感染人數不斷增加，對先進治療方案的需求不斷成長。根據聯合國愛滋病規劃署的資料，2020年6月，全球約有3,800萬人感染愛滋病毒。這種廣泛的患者基礎正在鼓勵製藥公司透過臨床研究積極投資愛滋病毒疫苗和藥物開發。世界衛生組織、比爾及梅琳達蓋茲基金會和國際藥品採購機制等組織增加愛滋病毒臨床研究的私人和公共資金可能會推動市場成長。例如，2020年11月，美國過敏和感染疾病研究所為美國的HIV臨床研究提供了大筆津貼。然而，與臨床試驗相關的較長時間和較高成本可能會阻礙市場成長。此外，與病人安全相關的監管障礙和倫理問題可能會阻礙愛滋病毒臨床試驗市場的成長。中國和印度等新興國家由於臨床研究成本低廉，可能在不久的將來為市場相關人員創造利潤豐厚的機會。

本研究的主要特點

本報告對全球HIV臨床試驗市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。

它還提供市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、吉利德科學公司、艾伯維公司、百時美施貴寶公司、葛蘭素史克公司、輝瑞公司、羅氏控股公司、賽諾菲公司、諾華公司、安斯泰來製藥公司、勃林格殷格翰有限公司、福泰製藥公司、安進公司Inc.、武田藥品工業株式會社等主要企業採取的競爭策略。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球愛滋病毒臨床試驗市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員可以透過用於分析全球愛滋病毒臨床試驗市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.48 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	5.80%	2031 Value Projection:	US$ 2.19 Bn

Global HIV clinical trials market growth is driven by rising number of clinical studies conducted worldwide to develop effective therapies and vaccines for HIV treatment and prevention. Biopharmaceutical companies and research organizations are increasingly investing in HIV clinical research and development activities due to growing HIV patient population. Furthermore, increasing awareness regarding clinical trials and availability of government as well as private can aid the market expansion. However, long durations and high costs associated with HIV clinical studies can pose challenges.

Market Dynamics

Global HIV clinical trials market growth is primarily driven by growing need for advanced treatment options due to increasing prevalence of HIV infections worldwide. In June 2020, as per UNAIDS data, around 38 million people lived with HIV globally in 2020. This wide patient base encourages pharmaceutical players to invest aggressively in HIV vaccine and drug development through clinical research. Rising private and public funding for HIV clinical studies from organizations like WHO, Bill & Melinda Gates Foundation, and UNITAID can drive the market growth. For instance, in November 2020, the National Institute of Allergy and Infectious Diseases provided significant grants for HIV clinical studies in the U.S. However, long timeline and high costs associated with clinical trials can hamper the market growth. Moreover, regulatory hurdles and ethical issues pertaining to patient safety can hamper the growth of the HIV clinical trials market. Emerging nations like China and India with lower costs for clinical research could generate lucrative opportunities for market players in the near future.

Key Features of the Study

This report provides in-depth analysis of the global HIV clinical trials market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players like Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Roche Holding AG, Sanofi S.A., Novartis AG, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Vertex Pharmaceuticals Incorporated, Amgen Inc., and Takeda Pharmaceutical Company Limited

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global HIV clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HIV clinical trials market

Market Segmentation

Phase Insights (Revenue, USD Bn, 2019 - 2031)
- Phase I
- Phase II
- Phase III
- Phase IV
- Preclinical
Study Design Insights (Revenue, USD Bn, 2019 - 2031)
- Interventional Studies
- Observational Studies
- Expanded Access Studies
Sponsor Type Insights (Revenue, USD Bn, 2019 - 2031)
- Pharmaceutical & Biotechnology Companies
- Academic Research Institutes
- Government & Private Research Organizations
- Contract Research Organizations (CROs)
Indication Insights (Revenue, USD Bn, 2019 - 2031)
- HIV-1
- HIV-2
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Gilead Sciences, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Roche Holding AG
- Sanofi S.A.
- Novartis AG
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Takeda Pharmaceutical Company Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global HIV Clinical Trials Market, By Phase
- Global HIV Clinical Trials Market, By Study Design
- Global HIV Clinical Trials Market, By Sponsor Type
- Global HIV Clinical Trials Market, By Indication
- Global HIV Clinical Trials Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends

4. Global HIV Clinical Trials Market, By Phase, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phase IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global HIV Clinical Trials Market, By Study Design, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Interventional Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Observational Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Expanded Access Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global HIV Clinical Trials Market, By Sponsor Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Academic Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Government & Private Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global HIV Clinical Trials Market, By Indication, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
HIV-1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
HIV-2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global HIV Clinical Trials Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Phase, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Study Design, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Sponsor Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
Astellas Pharma Inc.
Boehringer Ingelheim GmbH
Vertex Pharmaceuticals Incorporated
Amgen Inc.
Takeda Pharmaceutical Company Limited